Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring demand for its Wegovy obesity drugs.
Ozempic, the diabetes medication popularly used as an “off-label” weight-loss drug, has helped thousands shed excess pounds.